CytoSorbents extends Avenue Capital loan maturity to July 2028
CTSO•CytoSorbents amended its Avenue Capital credit facility, reducing principal by $5.25 million to $12.25 million and extending maturity to July 1, 2028. The $6.25 million financing includes a $4 million registered direct offering and a $2.25 million debt-for-equity exchange.
1. Loan amendment
CytoSorbents amended its Avenue Capital credit facility on November 19, reducing principal by $5.25 million to $12.25 million. The amendment extends the loan’s maturity by one year to July 1, 2028, and extends interest-only payments by 15 months, through March 31, 2028.
2. Financing terms
The $6.25 million financing comprises a $4 million registered direct offering and a $2.25 million debt-for-equity exchange. Offering proceeds will fund a $3 million principal repayment, while Avenue will receive 455,465 common shares at $4.94 per share for the exchanged debt. CytoSorbents expects the debt reduction to save approximately $700,000 in interest expense over 12 months.




